Ariella Hemorrhoid Gel
- Manufacturer
- YITONGBADA (SHENZHEN) INTERNATIONAL TRADE CO., LTD
- Effective date
- 2024-06-25
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- legacy-cache
- Hydrated at
- 2026-08-01 20:59:45
Label at a glance#
ProductAriella Hemorrhoid Gel
Active ingredientPHENYLEPHRINE HYDROCHLORIDE, LIDOCAINE
Label structure1 sections
Contacts and useful links#
Label contents#
Full prescribing information#
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Drug Facts
OTC - ACTIVE INGREDIENT SECTION
Active ingredients Purpose
Lidocaine 6% ………………………….………...….Protectant Phenylephrine HCL 0.25%…………………………………………….……………………..Vasoconstrictor
OTC - PURPOSE SECTION
Uses
-helps relieve itching and discomfort associated with hemorrhoids - temporarily shrinks swelling and relieves burning and pain -soothes and protects irritated tissue
DOSAGE & ADMINISTRATION SECTION
For external and/or intrarectal use only
OTC - ASK DOCTOR SECTION
Ask a doctor before use if you have
-heart disease -high blood pressure - thyroid disease - diabetes -difficulty in urination due to enlargement of the prostate gland
OTC - ASK DOCTOR/PHARMACIST SECTION
Ask a doctor or pharmacist before use if you are presently taking a prescription drug for high blood pressure or depression.
OTC - WHEN USING SECTION
When using this product do not exceed the recommended daily dosage unless directed by a doctor
OTC - ASK DOCTOR SECTION
Stop and ask a doctor if - bleeding occurs -condition worsens or does not improve within 7 days -introduction of the applicator into the rectum causes additional pain -an allergic reaction occurs - symptom does not improve or if redness, irritation, swelling, pain or other symptoms develop or increase
OTC - PREGNANCY OR BREAST FEEDING SECTION
If pregnant or breast-feeding, ask a health professional before use.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children. In case of accidental ingestion, seek medical advice immediately or contact a Poison Control Center right away. (1-800-222-1222)
WARNINGS SECTION
Warnings
INDICATIONS & USAGE SECTION
Directions
-when practical, cleanse the affected area by patting or blotting with an appropriate cleansing wipe. Gently dry by patting or blotting with a tissue or a soft cloth before application.
-apply half the gel in the applicator to the external affected area (only applies if you have external symptoms)
-find a comfortable position and gently insert about ½ inch into the rectum.
-push the end of the applicator to apply the remaining gel inside the rectum (Both steps are necessary for both internal and external symptoms as external hemorrhoid often comes with internal hemorrhoid)
-dispose the applicator after use.
-avoid movement for 1-3 hours
-Children under 12 years of age: ask a doctor
OTHER SAFETY INFORMATION
Other information store at 15-25°C (59-77°F)
INACTIVE INGREDIENT SECTION
Inactive ingredients
Borneol, Carbomer Homopolymer, Chlorhexidine Acetate, Glycerin, Thymol
DailyMed Dashboard NDC Coverage#
Products#
Every source-derived product name is available through these pages.
- Ariella Hemorrhoid Gel
- Lidocaine, Phenylephrine HCL
- PHENYLEPHRINE HYDROCHLORIDE
- PHENYLEPHRINE
- BORNEOL
- CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE
- GLYCERIN
- CHLORHEXIDINE ACETATE
- THYMOL
- LIDOCAINE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 83364-007 | 83364-007-01 |
| 84010-001 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| PHENYLEPHRINE HYDROCHLORIDE | 04JA59TNSJ | ACTIB |
| BORNEOL | M89NIB437X | IACT |
| CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE | 0A5MM307FC | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| CHLORHEXIDINE ACETATE | 5908ZUF22Y | IACT |
| THYMOL | 3J50XA376E | IACT |
| LIDOCAINE | 98PI200987 | ACTIB |
Source Document#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 3842bbaf-dbd2-0fb2-e063-6394a90a65dd | 1bbf56f2-2f71-601b-e063-6294a90a6e99 | 2025-06-23 | Warnings | 1bbf56f2-2f71-601b-e063-6294a90a6e99 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.